SEARCH

SEARCH BY CITATION

References

  • 1
    Al-Zubairi A.S., Eid E.E.M. (2010) Molecular targets in the development of antidiabetic drugs. Int J Pharm;6:784795.
  • 2
    Tahrani A.A., Piya M.K., Kennedy A., Barnett A.H. (2010) Glycemic control in type 2 diabetes: targets and new therapies. Pharmacol Ther;125:328361.
  • 3
    Skyler J.S. (2004) Diabetes Mellitus: pathogenesis and treatment Strategies. J Med Chem;47:41134117.
  • 4
    Pratley R.E., Matfin G. (2007) Pre-diabetes: clinical relevance and therapeutic approach. Br J Diab Vasc Med;7:120129.
  • 5
    Chyan Y.J., Chuang L.M. (2007) Dipeptidyl peptidase-IV Inhibitors: an evolving treatment for type 2 diabetes from the incretin concept. Recent Pat Endocr Metab Immune Drug Discov;1:1524.
  • 6
    Wu J., Chen Y., Shi X., Gu W. (2009) Dipeptidyl peptidase IV (DPP IV): a novel emerging target for the treatment of type 2 diabetes. J Nan Jing Med Univ;23:228235.
  • 7
    Mest H.J., Mentlein R. (2005) Dipeptidyl peptidase inhibitors as new drugs for the treatment of type 2 diabetes. Diabetologia;48:616620.
  • 8
    Green D.E. (2007) New therapies for diabetes. Clin Cornerstone;8:5865.
  • 9
    Matuszek B., Lenart Lipińska M., Nowakowski A. (2007) Incretin hormones in the treatment of type 2 diabetes Part I: influence of insulinotropic gut-derived hormones (incretins) on glucose metabolism. Endokrynol Pol;58:522585.
  • 10
    Wideman R.D., Kieffer T.J. (2009) Mining incretin hormone pathways for novel therapies. Trends Endocrinol Metab;20:280286.
  • 11
    Ahren B. (2004) Enhancement or prolongation of GLP-1 activity as a strategy for treatment of type 2 diabetes. Drug Discov Today Ther Strateg;1:207212.
  • 12
    Brandt I., Joossens J., Chen X., Maes M.B., Scharpe S., Meester I.D., Lambeir A.M. (2005) Inhibition of dipeptidyl-peptidase IV catalyzed peptide truncation by vildagliptin ((2S)-{[(3-hydroxyadamantan-1-yl)amino]acetyl}-pyrrolidine-2-carbonitrile). Biochem Pharmacol;70:134143.
  • 13
    Brigance R.P., Meng W., Fura A., Harrity T., Wang A., Zahler R., Kirby M.S., Hamann L.G. (2010) Synthesis and SAR of azolopyrimidines as potent and selective dipeptidyl peptidase-4 (DPP4) inhibitors for type 2 diabetes. Bioorg Med Chem Lett;20:43954398.
  • 14
    Deng J., Peng L., Zhang G., Lan X., Li C., Chen F., Zhou Y., Lin Z., Chen L., Dai R., Xu H., Yang L., Zhang X., Hu W. (2011) The highly potent and selective dipeptidyl peptidase IV inhibitors bearing a thienopyrimidine scaffold effectively treat type 2 diabetes. Eur J Med Chem;46:7176.
  • 15
    Wallace M.B., Feng J. (2008) Structure-based design and synthesis of benzimidazole derivatives as dipeptidyl peptidase IV inhibitors. Bioorg Med Chem Lett;18:23622367.
  • 16
    Cheon H.G., Lee C.M., Kim B.T., Hwang K.J. (2004) Lead discovery of quinoxalinediones as an inhibitor of dipeptidyl peptidase-IV (DPP-IV) by high-throughput screening. Bioorg Med Chem Lett;14:26612664.
  • 17
    Zhu Y., Xia S., Zhu M., Yi W., Cheng J., Song G., Li Z., Lu P. (2010) Synthesis, biological assay in-vitro and molecular docking studies of new imidazopyrazinone derivatives as potential dipeptidyl peptidase IV inhibitors. Eur J Med Chem;45:49534962.
  • 18
    Eckhardt M., Hauel N., Himmelsbach F., Langkopf E., Nar H., Mark M., Tadayyon M., Thomas L., Guth B., Lotz R. (2008) 3,5-Dihydro-imidazo[4,5-d]pyridazin-4-ones: a class of potent DPP-4 inhibitors. Bioorg Med Chem Lett;18:31583162.
  • 19
    Kurukulasuriya R., Rohde J.J., Szczepankiewicz B.G., Basha F., Lai C., Jae H.S., Winn M., Stewart K.D., Longenecker K.L., Lubben T.W., Ballaron S.J., Sham H.L., Geldern T.W.V. (2006) Xanthine mimetics as potent dipeptidyl peptidase IV inhibitors. Bioorg Med Chem Lett;16:62266230.
  • 20
    Gupta R.C., Chhipa L., Mandhare A.B., Zambad S.P., Chauthaiwale V., Nadkarni S.S., Dutt C. (2009) Novel N-substituted 4-hydrazino piperidine derivative as a dipeptidyl peptidase IV inhibitor. Bioorg Med Chem Lett;19:50215025.
  • 21
    Havale S.H., Pal M. (2009) Medicinal chemistry approaches to the inhibition of dipeptidyl peptidase-4 for the treatment of type 2 diabetes. Bioorg Med Chem;17:17831802.
  • 22
    Carson Denis A., Cottam Howard B., Lynn D. (2000) Thiazolopyrimidines useful as TNF-α Inhibitors; WO 00/69861.
  • 23
    Weir G.C., Clore E.E., Zma-Chinsky C.J., Bonnier-weir S. (1981) Islet secretion in new experimental model of non-insulin dependent diabetes. Diabetes Metab Rev;30:590594.
  • 24
    Abeeleh M.A., Ismail Z.B., Alzaben K.R., Halaweh S., Al-Essa M.K., Abuabeeleh J., Alsmady M.M. (2009) Induction of diabetes mellitus in rats using intraperitoneal streptozotocin: a comparison between 2 strains of rats. Eur J Sci Res;32:398402.
  • 25
    Singh S., Sethi S., Khanna V., Benjamin B., Kant R., Sattigeri J., Bansal V.S., Bhatnagar P.K., Davis J.A. (2011) RBx-0597, a potent, selective and slow-binding inhibitor of dipeptidyl peptidase IV for the treatment of type 2 diabetes. Eur J Pharmacol;652:157163.
  • 26
    Yamazaki K., Yasuda N., Inoue T., Nagakura T., Kira K., Shinoda M., Saeki T., Tanaka I. (2006) 7-But-2-ynyl-9-(6-methoxy-pyridin-3-yl)-6-piperazin-1-yl-7,9-dihydro-purin-8-one is a novel competitive and selective inhibitor of dipeptidyl peptidase IV with an antihyperglycemic activity. J Pharmacol Exp Ther;319:12531257.
  • 27
    Edmondson S.D., Mastracchio A., Mathvink R.J., He J., Harper B., Park Y.J., Beconi M. et al. (2006) (2S,3S)-3-Amino-4-(3,3-difluoropyrrolidin-1-yl)-N,N-dimethyl-4-oxo-2-(4-[1,2,4]triazolo [1,5-a]-pyridin-6-ylphenyl)butanamide: a selective α-aminoamide dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. J Med Chem;49:36143627.
  • 28
    Brooks B.R., Bruccoleri R.E., Olafson B.D., States D.J., Swaminathan S., Karplus M. (1983) CHARMM: a program for macromolecular energy, minimization, and dynamics calculations. J Comp Chem;4:187217.
  • 29
    Momany F.A., Rone R. (1992) Validation of the general purpose QUANTA ®3.2/CHARMm® force field. J Comp Chem;13:888900.
  • 30
    Discovery Studio 1.7 (2006) Molecular Modeling Program Package. San Diego, CA, USA: Accelrys Software Inc.
  • 31
    Halgren T.H. (1996) Merck molecular force field. I. Basis, form, scope, parameterization, and performance of MMFF94. J Comp Chem;17:490519.
  • 32
    Venkatachalam C.M., Jiang X., Oldfield T., Waldman M. (2003) LigandFit: a novel method for the shape-directed rapid docking of ligands to protein active sites. J Mol Graph Model;21:289307.
  • 33
    Kim D., Wang L., Beconi M., Eiermann G.J., Fisher M.H., He H., Hickey G.J., et al. (2005) (2R)-4-Oxo-4-[3-(Trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl) butan-2-amine: a potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. J Med Chem;48:141151.